Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: clochard who wrote (2404)	2/18/1998 9:34:00 PM
From: Brander	Read Replies (3) \| Respond to of 7041

Zonagen bounced off 20 today, and 20 is the number the most vocal short said it would never reach again. Wasn't it supposed to crash over the last two days? It declined a little, but could not fall through 20 where there seems to be some support. The next week of trading will be very revealing as to the short term trend. Some notes: A 50% drop out rate is not good, but many initial trials do have high drop out rates. This is indicative of uncomfortable side effects, and the dosages and schedule of administration will probably be altered for repeat trials (if this report is true). Also, I toured the Dept of Urology and Vanderbilt Univ Hosp today. I had a brief conversation with a Urologist. He was familiar with Phentolamine, and said it "had potential but the jury is still out" in the treatment of impotence. He also confirmed the obvious--the market is huge, and any drug that gets approved by the FDA for ED will be tried out extensively initially. Long term success will depend on the results that patients report to their docs. I am not sold on ZONA yet, and I don't have a position in ZONA. I do think it is an interesting speculative stock, and I am certainly not convinced that it is a scam.